By Patrick Wingrove and Bhanvi Satija
(Reuters) – Johnson & Johnson (NYSE:), contemporary off a $14.6 billion deal to purchase neurological drugmaker Intra-Mobile, reported fourth-quarter gross sales and revenue above Wall Road estimates on Wednesday, pushed by robust gross sales of its most cancers remedies.
The New Jersey-based drugmaker additionally mentioned it expects 2025 gross sales of between $90.9 billion and $91.7 billion and to earn between $10.75 and $10.95 per share on an adjusted foundation. Analysts had been anticipating gross sales of $90.98 billion and a revenue of $10.56 per share for 2025, in line with knowledge compiled by LSEG.
J&J’s fourth-quarter gross sales stood at $22.52 billion, up 5.3% from a 12 months in the past and above analysts’ expectations of $22.42 billion, in line with LSEG knowledge.
On an adjusted foundation, the corporate earned $2.04 per share within the quarter – which features a 22 cents cost associated to its acquisition of medical device-maker V-Wave – practically 11% decrease than the earlier 12 months however beating analysts’ estimates of $2.01 per share.
Quarterly gross sales of J&J’s most cancers medicine rose 19% worldwide, pushed by greater than $3 billion for a number of myeloma remedy Darzalex, which was up 20.9% from a 12 months in the past.
“Darzalex continues to be a pillar model with respect to efficiency,” mentioned J&J Chief Monetary Officer Joe Wolk in an interview, noting that gross sales from Shockwave Medical (NASDAQ:) additionally helped drive development.
The corporate is fostering development at its medical machine unit via offers targeted on coronary heart well being – together with its $13.1 billion deal to amass Shockwave Medical.
Shockwave generated $258 million in gross sales for the quarter and $564 million for the 12 months, in line with J&J.
J&J’s revolutionary drugs unit introduced in fourth-quarter gross sales of $14.33 billion whereas its medtech unit generated $8.19 billion, up 4.4% and 6.7% respectively in comparison with a 12 months in the past.
Gross sales of J&J’s blockbuster psoriasis remedy Stelara fell 14.7% to $2.35 billion within the fourth quarter. Analysts’ had been anticipating gross sales of $2.25 billion, in line with LSEG knowledge.
Shut copies of Stelara launched in Europe, Canada and some different markets final 12 months. A number of Stelara biosimilars are anticipated to launch within the U.S. this 12 months.
For the total 12 months, Stelara introduced in income of $10.36 billion, making up greater than 18% of J&J’s whole drug gross sales of $56.96 billion for 2024. Analysts had been anticipating gross sales of $10.59 billion.
Annual gross sales of the drug are anticipated to fall to about $7 billion this 12 months.
Darzalex introduced in annual gross sales of $11.67 billion, making it J&J’s biggest-selling drug. Analysts had been anticipating gross sales of $11.11 billion for this 12 months.
